Subrata Ghosh

Articles in Scholarly Journals [Incomplete List]

  1. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes
    Gut, vol. 56, no. 2, pp. 168–175, 2007
  2. The classics in perspective
    Gut, vol. 56, no. 9, pp. 1184–1186, 2007
  3. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?
    Gut, vol. 55, no. 1, pp. 6–8, 2006
  4. Gastroprotective effects of oral nucleotide administration
    Gut, vol. 55, no. 2, pp. 165–171, 2006
  5. Novel Treatment Options for Inflammatory Bowel Disease
    Drugs, vol. 66, no. 9, pp. 1179–1189, 2006
  6. Modulation of dendritic cell phenotype and functionin anin vitromodel of the intestinal epithelium
    European Journal of Immunology, vol. 36, no. 4, pp. 864–874, 2006
  7. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease
    European Journal of Immunology, vol. 36, no. 6, pp. 1629–1635, 2006
  8. How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?
    Nature Clinical Practice Gastroenterology & Hepatology, vol. 3, no. 10, Article ID ncpgasthep0605, 1 pages, 2006
  9. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure
    Clinical Science, vol. 110, no. 5, p. 563, 2006
  10. Effects of Mouse and Human Lipocalin Homologues 24p3/lcn2 and Neutrophil Gelatinase–Associated Lipocalin on Gastrointestinal Mucosal Integrity and Repair
    Gastroenterology, vol. 131, no. 3, pp. 809–817, 2006
  11. Detection of Muramyl Dipeptide-Sensing Pathway Defects in Patients with Crohn's Disease
    Inflammatory Bowel Diseases, vol. 12, no. 7, pp. 598–605, 2006
  12. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence
    Alimentary Pharmacology and Therapeutics, vol. 24, no. s1, pp. 2–9, 2006
  13. Chronic Exposure to Helicobacter pylori Impairs Dendritic Cell Function and Inhibits Th1 Development
    Infection and Immunity, vol. 75, no. 2, pp. 810–819, 2006
  14. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis
    Alimentary Pharmacology and Therapeutics, vol. 21, no. 11, pp. 1357–1364, 2005
  15. Reparative properties of a commercial fish protein hydrolysate preparation
    Gut, vol. 54, no. 6, pp. 775–781, 2005
  16. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease
    Gut, vol. 54, no. 11, pp. 1553–1557, 2005
  17. Infliximab in refractory coeliac disease
    European Journal of Gastroenterology & Hepatology, vol. 17, no. 6, pp. 603–604, 2005
  18. Infliximab use in Crohn??s disease: impact on health care resources in the UK
    European Journal of Gastroenterology & Hepatology, vol. 17, no. 10, pp. 1047–1052, 2005
  19. A common CTLA4 haplotype associated with coeliac disease
    European Journal of Human Genetics, vol. 13, no. 4, Article ID 5201357, 4 pages, 2005
  20. Synergistic enhancement of Toll-like receptor responses by NOD1 activation
    European Journal of Immunology, vol. 35, no. 8, pp. 2471–2476, 2005
  21. Cytokines and growth factor modulators in intestinal inflammation and repair
    The Journal of Pathology, vol. 205, no. 4, pp. 417–425, 2005
  22. Anisakiasis?a neglected diagnosis in the West
    Digestive and Liver Disease, vol. 37, no. 1, pp. 7–9, 2005
  23. Prediction of response to infliximab in Crohn's disease
    Digestive and Liver Disease, vol. 37, no. 8, pp. 559–563, 2005
  24. Muramyl dipeptide and toll-like receptor sensitivity in -associated Crohn's disease
    The Lancet, vol. 365, no. 9473, pp. 1794–1796, 2005
  25. Interfering with interferons in inflammatory bowel disease
    Gut, vol. 55, no. 8, pp. 1071–1073, 2005
  26. Does innate immune response defect underlie inflammatory bowel disease in the Asian population?
    Postgraduate Medical Journal, vol. 81, no. 958, pp. 483–485, 2005
  27. Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients
    Journal of Cell Science, vol. 117, no. 10, pp. 1989–1999, 2004
  28. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis
    Peptides, vol. 25, no. 5, pp. 793–801, 2004
  29. Mechanism of intestinal entry of infectious prion protein in the pathogenesis of variant Creutzfeldt–Jakob disease
    Advanced Drug Delivery Reviews, vol. 56, no. 6, pp. 915–920, 2004
  30. Growth factors and trefoil peptides in gastrointestinal health and disease
    Current Opinion in Pharmacology, vol. 4, no. 6, pp. 567–571, 2004
  31. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study
    Alimentary Pharmacology and Therapeutics, vol. 20, no. 11-12, pp. 1337–1346, 2004
  32. Maintenance therapy versus episodic therapy with infliximab for Crohn's disease
    Nature Clinical Practice Gastroenterology & Hepatology, vol. 1, no. 2, Article ID ncpgasthep0039, 1 pages, 2004
  33. Incidence of juvenile-onset Crohn?s disease in Scotland: Association with northern latitude and affluence
    Gastroenterology, vol. 127, no. 4, pp. 1051–1057, 2004
  34. Probiotics in inflammatory bowel disease: is it all gut flora modulation?
    Gut, vol. 53, no. 5, pp. 620–622, 2004
  35. Effects of growth factors and receptor blockade on gastrointestinal cancer
    Gut, vol. 53, no. 8, pp. 1059–1063, 2004
  36. Natalizumab for Active Crohn's Disease
    New England Journal of Medicine, vol. 348, no. 1, pp. 24–32, 2003
  37. NATALIZUMAB: ANOTHER ???SMART-DRUG??? FOR CROHN'S DISEASE
    Evidence-Based Gastroenterology, vol. 4, no. 2, pp. 48–49, 2003
  38. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome
    Digestive and Liver Disease, vol. 35, no. 8, pp. 546–551, 2003
  39. Bioactive natural compounds for the treatment of gastrointestinal disorders
    Clinical Science, vol. 104, no. 6, p. 547, 2003
  40. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab
    Expert Opinion on Biological Therapy, vol. 3, no. 6, pp. 995–1000, 2003
  41. Management of Crohn's disease from efficacy, quality of life and health economic perspectives
    Expert Review of Pharmacoeconomics Outcomes Research, vol. 3, no. 5, pp. 587–598, 2003
  42. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial
    Gut, vol. 52, no. 7, pp. 998–1002, 2003
  43. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?
    Alimentary Pharmacology and Therapeutics, vol. 16, no. 5, pp. 857–867, 2002
  44. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study
    Alimentary Pharmacology and Therapeutics, vol. 16, no. 11, pp. 1917–1922, 2002
  45. Whole gut lavage fluid interleukin-1ß and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission
    Digestive and Liver Disease, vol. 34, no. 6, pp. 424–429, 2002
  46. Anti-inflammatory effects of enteral diet components on Crohn's disease-affected tissues in vitro
    Digestive and Liver Disease, vol. 34, no. 6, pp. 430–438, 2002
  47. Intestinal Entry of Prions
    Zeitschrift für Gastroenterologie, vol. 40, no. 1, pp. 37–40, 2002
  48. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience
    Alimentary Pharmacology and Therapeutics, vol. 15, no. 10, pp. 1639–1646, 2001